Targeted Clinical Cancer Trials
Where can I find information about clinical trials of targeted therapies?
What is Clinical Research?
For more information, please call our toll-free number (833) 330-0930 or contact us via email info@goodclinicaltrials.com
Targeted Cancer Therapies Was Studied in Clinical Trials:
- Alemtuzumab (Campath®)
- Alitretinoin (Panretin®)
- Anastrozole (Arimidex®)
- Bevacizumab (Avastin®)
- Bexarotene (Targretin®)
- Bortezomib (Velcade®)
- Cetuximab (Erbitux®)
- Dasatinib (Sprycel®)
- Denileukin diftitox (Ontak®)
- Erlotinib hydrochloride (Tarceva®)
- Everolimus (Afinitor®)
- Exemestane (Aromasin®)
- Fulvestrant (Faslodex®)
- Gefitinib (Iressa®)
- Ibritumomab tiuxetan (Zevalin®)
- Imatinib mesylate (Gleevec®)
- Lapatinib ditosylate (Tykerb®)
- Letrozole (Femara®)
- Nilotinib (Tasigna®)
- Ofatumumab (Arzerra®)
- Panitumumab (Vectibix®)
- Pazopanib hydrochloride (Votrient®)
- Pralatrexate (Folotyn®)
- Rituximab (Rituxan®)
- Romidepsin (Istodax®)
- Sorafenib tosylate (Nexavar®)
- Sunitinib malate (Sutent®)
- Tamoxifen
- Temsirolimus (Torisel®)
- Toremifene (Fareston®)
- Tositumomab and 131I-tositumomab (Bexxar®)
- Trastuzumab (Herceptin®)
- Tretinoin (Vesanoid®)
- Vorinostat (Zolinza®)
Head and Neck Cancer Clinical Trial
If you or a family member 18 years of age or older has been diagnosed with cancer of the throat or mouth, you may qualify for a clinical trial and will receive study treatment and compensation. Please click on the link below for more information:
Multiple Myeloma:
We are enrolling participants 18 and older in a clinical study for Multiple Myeloma. To qualify, you must:
- Have been diagnosed with Multiple Myeloma
- Have received at least 1 prior line of anti-myeloma therapy
- Have documented evidence of progressive disease on or after the last regimen
Participants may receive compensation and study treatment.
Please contact us for more information.
Chronic Myeloid Leukemia (CML)
If you are 18 years of age or older and have been newly diagnosed with Chronic Myeloid Leukemia or have received prior treatment with imatinib, or nilotinib, or dasatinib or bosutinib for 4 weeks or less, you may qualify for a clinical study.
Participants may receive compensation and study treatment.
Please contact us for more information.
Contact Us Today:
Located: 3465 Nazareth Road, Suite 102 Easton, PA 18045
Phone: (833) 330-0930
Text: 717-819-9982
Email: info@goodclinicaltrials.com